摘要
内皮素是迄今所发现的体内最强的缩血管物质,其与不同亚型的膜受体(包括内皮素受体A(endothelin receptor A,ETA)、B及C)结合后,产生不同甚至相反的病理生理效应。ETB受体主要参与内皮素的清除、血管舒张、水盐平衡,调节细胞增殖或凋亡,似乎作为"保护性受体"发挥作用。在多种心血管疾病发生、发展过程中,由于ETB受体调节异常,这种保护作用被减弱甚至逆转。本文对ETB受体的分布、信号途径、调节方式的研究进展予以综述。
Up to now, endothelin is still treated as the most potent vasoconstrictor peptide, which presents different,even reverse pathophysiological effects by binding to different receptor subtypes, including endothelin receptor A (ETA) , B (ETB) and C (ETC). ETB receptor has been demonstrated to take part in the clearance of endothelin, endothelial-cell mediated vasodilation,inhibition of sodium reabsoprtion and regulation of cells proliferation or apoptosis as protective acceptor. During the occurrence and development of varied cardiovascular diseases, abnormal regulation role of ETB receptor may weak or reverse the protection effect of ETB. This article reviewed the advancement in distribution, signal transduction and regulation mode of ETB receptor.
出处
《医学综述》
2008年第12期1799-1801,共3页
Medical Recapitulate
关键词
内皮素B型受体
内皮素
心血管疾病
Endothelin receptor type B
Endothelin
Cardiovascular diseases